Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US WorldMeds' Opioid Withdrawal Drug Lofexidine Heads To US FDA Panel

Executive Summary

Sponsor seeks a novel claim for facilitating completion of opioid discontinuation treatment, but agency's external experts will weigh in on evidentiary threshold for such an indication; FDA staff give mixed review to patient-reported outcomes instrument used as primary endpoint in two pivotal trials.

You may also be interested in...



Keeping Track: A Diverse Array Of Approvals, A CRL For Evolus' Botox Competitor, And Coherus Refiles Neulasta Biosimilar

The latest drug development news and highlights from our US FDA Performance Tracker.

Opioid Withdrawal Symptom Mitigation Data Can Support A Labeling Claim

While symptom reduction is a clinically meaningful benefit that can support an indication, data on withdrawal treatment completion can provide confirmatory evidence of a drug's effect, US FDA advisory committee members say in their review of US WorldMeds' lofexidine.

Lofexidine Gets US FDA Panel Nod For Mitigating Opioid Withdrawal Symptoms

But Psychopharmacologic Drugs Advisory Committee says US WorldMeds' second proposed indication for facilitating completion of opioid discontinuation treatment is not supported by data from two short-term studies in an 'idealized' population.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS122772

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel